LIVN - LivaNova PLC
| Previous Close | 72.11 |
| Open | 71.65 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 70.74 - 72.15 |
| 52 Week Range | 64.80 - 131.54 |
| Volume | 248,752 |
| Avg. Volume | 672,204 |
| Market Cap | 3.448B |
| Beta (3Y Monthly) | 0.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.49 |
| Earnings Date | Jul 30, 2019 - Aug 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 88.14 |
- Business Wire•8 days ago
LivaNova to Present at the UBS Global Healthcare Conference
LivaNova PLC (LIVN), a market-leading medical technology company, today announced Damien McDonald, Chief Executive Officer, and Thad Huston, Chief Financial Officer, will present at the UBS Global Healthcare Conference on Wednesday, May 22 in New York at 10 a.m. Eastern Time. LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world.
- Markit•17 days ago
See what the IHS Markit Score report has to say about LivaNova PLC.
LivaNova PLC NASDAQ/NGS:LIVNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for LIVN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding LIVN totaled $1.27 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Business Wire•21 days ago
New Data Emphasizing LivaNova Perceval Valve Durability to be Presented at the American Association for Thoracic Surgery Meeting
LivaNova PLC (LIVN), a market-leading medical technology company, today announced that new clinical data for its sutureless surgical aortic valve, Perceval®, will be unveiled at this year’s American Association for Thoracic Surgery (AATS) meeting. On May 4, Prof. Bart Meuris from Leuven University Hospital (BE) will present the data from his center’s 11-year clinical experience with Perceval, which represents the longest clinical follow-up for the valve that has been published. Of particular significance in the findings is the absence of explants due to structural valve deterioration (SVD), as well as the low rate of paravalvular leak (PVL) reported.
Motley Fool•22 days agoLivanova (LIVN) Q1 2019 Earnings Call Transcript
LIVN earnings call for the period ending March 31, 2019.
- Associated Press•23 days ago
LivaNova: 1Q Earnings Snapshot
On a per-share basis, the London-based company said it had a loss of 31 cents. Earnings, adjusted for non-recurring costs and amortization costs, were 54 cents per share. The results exceeded Wall Street ...
- Business Wire•23 days ago
LivaNova Reports First Quarter 2019 Results
LivaNova PLC , a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2019.
- Insider Monkey•last month
Were Hedge Funds Right About Fleeing LivaNova PLC (LIVN)?
Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]
- Associated Press•2 months ago
Snap and Apache jump while Boston Beer, LivaNova slip
Stocks that moved substantially or traded heavily on Friday: Duluth Holdings Inc., down $5.94 to $17.60 The clothing retailer's fourth-quarter profit and revenue fell short of Wall Street forecasts. LivaNova ...
- Motley Fool•2 months ago
Why Duluth Holdings, LivaNova, and Boston Beer Slumped Today
These stocks lost ground even as the broader market posted solid gains.
- Motley Fool•2 months ago
Here's Why LivaNova Plummeted Today
The medical-device company posted tepid preliminary first-quarter revenue.
- TheStreet.com•2 months ago
LivaNova Falls as Medical Device Company Preannounces Weak Revenue
, the medical device maker, tanked hard Friday after the company preannounced weak revenue for its fiscal first quarter. Sales for the first quarter of 2019 are expected at $251 million, flat year over year, and about 5.3% below Wall Street's consensus. Wall Street's expects first-quarter profit of 65 cents.
- Business Wire•2 months ago
LivaNova Reports Preliminary Unaudited First Quarter 2019 Revenue Results
LivaNova PLC , a market-leading medical technology company, today announced preliminary unaudited revenue results for the quarter ended March 31, 2019.
- Business Wire•2 months ago
LivaNova to Present at the Needham Healthcare Conference
LivaNova PLC (LIVN), a market-leading medical technology company, today announced Thad Huston, Chief Financial Officer of LivaNova, will present at the Needham Healthcare Conference on Tuesday, April 9 in New York at 2:10 p.m. Eastern Daylight Time. LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world.
- Business Wire•2 months ago
LivaNova Announces Settlement Agreement to Resolve Certain Litigation in the U.S. Related to the 3T Heater-Cooler Device
LivaNova PLC (LIVN), a market-leading medical technology company, today announced an agreement to settle approximately 75 percent of the previously disclosed litigation in the U.S. related to the Company’s 3T Heater-Cooler device. Under the terms of the agreement and subject to certain conditions, including acceptance of the settlement by individual claimants, the Company has agreed to a settlement framework that provides for a comprehensive resolution of the personal injury cases pending in the multi-district litigation in U.S. federal court, a related class action case pending in U.S. federal court, as well as certain cases in state courts across the U.S. The agreement provides for a total payment of up to $225 million to resolve the claims covered by this settlement, with up to $135 million to be paid no earlier than July 2019 and the remainder in January 2020.
- Business Wire•2 months ago
LivaNova Announces Trui Hebbelinck as Chief Human Resources Officer
LivaNova PLC (LIVN), a market-leading medical technology company, today announced Trui Hebbelinck has been appointed Chief Human Resources Officer for the Company. Hebbelinck will lead global human resources, serve on the Executive Leadership Team and report to Chief Executive Officer Damien McDonald. “Trui brings incredible expertise to LivaNova and has a history of exceptional results,” said McDonald.
- Business Wire•2 months ago
LivaNova to Present Autonomic Regulation Therapy Findings for Chronic Heart Failure Patients at the American College of Cardiology 68th Annual Scientific Session
LivaNova PLC (LIVN), a market-leading medical technology company, today announced it will present three abstracts supporting the use of implantable neuromodulation technology to treat chronic heart failure during the American College of Cardiology 68th Annual Scientific Session (ACC 2019) from March 16-18 in New Orleans, USA. The LivaNova VITARIA® System delivers Autonomic Regulation Therapy (ART) using Vagus Nerve Stimulation (VNS) to treat patients with chronic, symptomatic heart failure with reduced ejection fraction (HFrEF). VITARIA is currently being used to study the effects of ART in a prospective, international, randomized, controlled clinical trial (ANTHEM-HFrEF Pivotal Study).
- GlobeNewswire•3 months ago
Investor Expectations to Drive Momentum within Amarin, PulteGroup, LivaNova, Teva Pharmaceutical Industries, Viad, and Activision Blizzard — Discovering Underlying Factors of Influence
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Motley Fool•3 months agoLivaNova PLC (LIVN) Q4 2018 Earnings Conference Call Transcript
LIVN earnings call for the period ending December 31, 2018.
- Business Wire•3 months ago
LivaNova Reports Fourth Quarter and Full-Year 2018 Results
LivaNova PLC , a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2018.
- Business Wire•3 months ago
LivaNova Announces Availability of Safety and Technical Information for Valve-in-Valve Procedures on Perceval Platform
LivaNova PLC (LIVN), a market-leading medical technology company, announced today that given the increasing viability of Valve-in-Valve (ViV) procedures, it has added new safety and technical information to the Perceval U.S. Instructions For Use (IFUs). This addition was made following completion of the Company’s application to the U.S. Food and Drug Administration. The use of transcatheter valves in failed bioprostheses has recently been recognized in both American and European Guidelines as an option for patients at high surgical risk.
